Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension

European Respiratory Journal

Volumn 50, Issue 2, 2017, Pages

  Gaine, Sean ^a   Chin, Kelly ^b   Coghlan, Gerry ^c   Channick, Richard ^d   Di Scala, Lilla ^e   Galiè, Nazzareno ^f   Ghofrani, Hossein Ardeschir ^g,h,i   Lang, Irene M ^j   McLaughlin, Vallerie ^k   Preiss, Ralph ^e   Rubin, Lewis J ^l   Simonneau, Gérald ^m,n,o   Sitbon, Olivier ^m,n,o   Tapson, Victor F ^p   Hoeper, Marius M ^q  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ACTELION PHARMACEUTICALS LTD   (Switzerland)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

^h Excellence Cluster Cardio Pulmonary System   (Germany)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m BICÊTRE HOSPITAL   (France)

ⁿ UNIVERSITÉ PARIS SACLAY   (France)

^o CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^p CEDARS SINAI MEDICAL CENTER   (United States)

^q HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SELEXIPAG; ACETAMIDE DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEADACHE; HOT FLUSH; HUMAN; JAW PAIN; LIMB PAIN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THORAX PAIN; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; RISK ASSESSMENT; SURVIVAL ANALYSIS;

ACETAMIDES; ADULT; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PYRAZINES; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SURVIVAL ANALYSIS;

EID: 85027881389     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02493-2016     Document Type: Article

References (27)

1. Mathai SC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin 2012; 8: 413-425.
2. McLaughlin V, Humbert M, Coghlan G, et al. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009; 48: Suppl. 3, iii25-iii31.
3. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
4. Kähler CM, Colleselli D. Pulmonary arterial hypertension (PAH) in connective tissue diseases. Rheumatology (Oxford) 2006; 45: Suppl. 3, iii11-iii13.
5. Rhee RL, Gabler NB, Sangani S, et al. Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 1111-1117.
6. Johnson SR, Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 2011; 20: 277-286.
7. Distler O, Pignone A. Pulmonary arterial hypertension and rheumatic diseases - from diagnosis to treatment. Rheumatology (Oxford) 2006; 45: Suppl. 4, iv22-iv25.
8. Pulido T, Adzerikho I, Channick R, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818.
9. Coghlan JG, Galie N, Barbera JA, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2017; 76: 1219-1227.
10. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522-2533.
11. Condliffe R, Howard LS. Connective tissue disease-associated pulmonary arterial hypertension. F1000Prime Rep 2015; 7: 6.
12. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
13. Schreiber BE, Connolly MJ, Coghlan JG. Pulmonary hypertension in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2013; 27: 425-434.
14. Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest 2015; 148: 1043-1054.
15. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-1394.
16. Avouac J, Wipff J, Kahan A, et al. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008; 67: 808-814.
17. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
18. Ramjug S, Hussain N, Hurdman J, et al. Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Respirology 2017; 22: 372-377.
19. Humbert M, Coghlan JG, Ghofrani HA, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017; 76: 422-426.
20. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29: 469-475.
21. European Medicines Agency. European Public Assessment Report: Uptravi (selexipag) 2016. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/003774/WC500207175.pdf Date last accessed: March 15, 2017. Date last updated: April 1, 2016.
22. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192-1201.
23. Farber HW, Miller DP, McGoon MD, et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant 2015; 34: 362-368.
24. Rhee RL, Gabler NB, Praestgaard A, et al. Adverse events in connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol 2015; 67: 2457-2465.
25. Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013; 144: 952-958.
26. Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized controlled trial. Circulation 2013; 127: 624-633.
27. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C Study): a randomized controlled trial. Chest 2012; 142: 1383-1390.